Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1324 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

BioCryst reports influenza drug study results

Peramivir is an intravenously administered investigational anti-viral agent, which delivers high plasma concentrations to the sites of infection. The open-label, randomised, safety and virology Phase III study evaluated

FDA approves Lupin Pharma Nabumetone tablets

Nabumetone is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs) and it works by reducing hormones that cause inflammation and pain in the body. Nabumetone is

Merck makes changes in Vorapaxar trials

Tracer trial is evaluating patients with acute coronary syndrome; however, TRA-2P (also known as TIMI 50) is assessing patients with prior heart attack, stroke and peripheral artery disease.

Orexo, Invida sign supply pact

As per the terms of the agreement, Orexo is expected to take up the responsibly for supplying Abstral product to Invida. However, Invida will be responsible for all

Eisai opens sales, marketing operation in Netherlands

Eisai‘s sales and marketing operation will initially market epilepsy treatment drug Zonegran (zonisamide) in the Netherlands. Eisai Netherlands managing director Gert-Jan Kouseband said Eisai’s entry into the country

Centice introduces Computational Raman technology platform

Raman Extended Computational Application Platform (RECAP) brings patented technology in computational sensors, materials verification and identification software to developers, solutions providers and equipment suppliers. Centice claims Recap is

IDEX agrees to acquire Microfluidics International

Microfluidics’ product and service offerings are expected to enhance IDEX’s micro fluidics and micro particle technology position. Microfluidics will operate as a stand-alone business within the IDEX Fluid